Apple could shift focus toward AI efforts as iPhone sales decline

Danielle Brown | | Health Exec | Precision Medicine

Apple could look to prioritize its AI efforts as iPhone sales decrease and the company seeks other growth areas, according to a recent report by CNBC.

Last month, Apple reported that sales for the iPhone—the company’s top product—were down 15 percent when compared to last year. The technology company hopes to generate revenue through additional services beyond its core product.

The recent revelation could point to the company being more heavily invested in AI. In December, Apple promoted John Giannandrea as its senior vice president of machine learning and AI strategy. In the new role, Giannandrea oversees the strategy for AI and machine learning across all Apple products and services, including the development of the company’s Core ML and Siri technologies.

Recently, Aetna, in collaboration with Apple, launched Attain—an AI-based health app that provides users with personalized health goals. The app is used in partnership with the Apple Watch to track daily activity levels, recommend healthy actions and improve nutrition and sleep habits.

To read the full report, click the link below.

Apple's priorities are shifting as iPhone sales continue to sink

""
Danielle Brown

Danielle covers Clinical Innovation & Technology as a senior news writer for TriMed Media. Previously, she worked as a news reporter in northeast Missouri and earned a journalism degree from the University of Illinois at Urbana-Champaign. She's also a huge fan of the Chicago Cubs, Bears and Bulls. 

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

Cardiovascular Business
Boston Scientific enters renal denervation market with acquisition worth up to $540M

Boston Scientific has announced another significant M&A deal, scooping up an Israeli medtech company focused on RDN technology. 

Radiology Business
Shift toward imaging outside the hospital could save billions

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Cardiovascular Business
FDA announces catheter recall for Johnson & Johnson PFA system due to stroke risk

The recall comes after approximately 3% of patients treated with the device during the early stages of its U.S. rollout experienced a stroke or transient ischemic attack following surgery. The expected stroke rate is closer to 1%, the FDA explained.